Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Sucampo Pharmacuticals (Nasdaq: SCMP) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Sucampo's business and see what CAPS investors are saying about the stock right now.

Sucampo facts

Headquarters Bethesda, Md.
Market Cap $293.2 million
Industry Pharmaceuticals
Trailing-12-Month Revenue $53.8 million
Management Co-Founder/Chairman/CEO Ryuji Ueno
CFO Cary Claiborne
Return on Equity (average, past 3 years) (12.1%)
Cash/Debt $75.2 million / $59.5 million
Competitors Ironwood Pharmaceuticals
Progenics Pharmaceuticals
Theravance

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 86% of the 79 members who have rated Sucampo believe the stock will outperform the S&P 500 going forward.   

Just this past weekend, one of those bulls, All-Star zzlangerhans, tapped the stock as a potentially timely opportunity:

Sucampo is retesting price levels seen shortly after the company announced positive results from the phase III trial of lubiprostone in opiate bowel dysfunction. The share price rose as high as [$8.50] but has been in a declining trend since the last earnings PR. An sNDA submission for lubiprostone in OBD is likely in the near future. Meanwhile, lubiprostone for chronic idiopathic constipation is bringing in about [$10 million-$14 million] per quarter and positive regulatory decisions are likely in Japan and Europe this coming quarter. Other potential short-term catalysts are a pending arbitration with partner Takeda and a long-delayed revised labeling for Rescula for glaucoma.

I'm not feeling a hard floor here but this seems like a suitable point [to] mark the stock in case it continues to decline in advance of positive catalysts.

If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Sucampo may not be your top choice.

If that's the case, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.